studies

756A AASLD ABSTRACTS HEPATOLOGY, October, 2015
1109
Lower 25-OH Vitamin D Levels are Associated With
Advanced Fibrosis in Chronic Hepatitis C Infection but
Pretreatment or Change in Level with Directing Acting
Antiviral Therapy Do Not Predict Sustained Virologic
Response
David W. Backstedt 1 , Mark Pedersen 2 , Bobby Kakati 1 , Myunghan
Choi 4 , Anil B. Seetharam 3 ; 1 Gastroenterology, Banner University
Medical Center, Phoenix, AZ; 2 Internal Medicine, Banner University
Medical Center, Phoenix, AZ; 3 University of Arizona College
of Medicine, Banner Transplant and Advanced Liver Disease Center,
Phoenix, AZ; 4 Arizona State University College of Nursing and
Health Innovation, Phoenix, AZ
Rationale: Recent reports suggest association between low
25-OH Vitamin D (Vit D) levels and advanced fibrosis in Hepatitis
C Virus (HCV) infection. Evaluation of the influence and
predictive value of pretreatment Vit D level on sustained virologic
response (SVR) with direct acting antiviral (DAA) therapy
is needed. Aim: Evaluate association of pre-treatment Vit
D level with stage of fibrosis in an HCV infected cohort and
assess change in level with DAA therapy. Secondary aim was
to assess predictive value of pre-treatment or change in Vit D
level on SVR12. Methods: Prospective study of chronic HCV
patients initiated on DAA. Consecutively enrolled patients
received: 1) pegylated interferon alfa 2a (IFN) + sofobuvir
(SOF) + ribavirin (RBV); 2) SOF + RBV; 3) SOF + Simeprevir
(SMV); and 4) Ledipasvir (LDV) + SOF; 5) LDV + SOF + RBV in
accordance with AASLD guidelines. Vit D levels were assessed
prior to initiation of treatment and at end of treatment response
(ETR). Pearson correlation coefficients were assessed followed
by repeated measures ANOVA to determine significant Vit D
level changes over time controlling for covariates: age, gender,
and BMI. Multivariate logistic regression was performed
to identify predictors of SVR12. Results: 218 patients completing
DAA regimen: IFN + SOF + RBV (n=37); SOF + RBV
(n=117); SMV + SOF (n=51), LDV+SOF (n=11), LDV +SOF
+RIBA (n=2). 61.5% genotype 1 and 56% cirrhosis. 64%
treatment naïve and 36% treatment experienced (26% non-responders,
10% relapsers). 98% (213/218) achieved ETR with
79% (172/218) achieving SVR12 (19% relapsers). Frequency
of low pre-treatment Vit D level (